Comparative Pharmacology
Head-to-head clinical analysis: TOBRADEX versus TOBRADEX ST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOBRADEX versus TOBRADEX ST.
TOBRADEX vs TOBRADEX ST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobradex is a combination of tobramycin (an aminoglycoside antibiotic) and dexamethasone (a corticosteroid). Tobramycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Dexamethasone is a corticosteroid that suppresses inflammation by binding to glucocorticoid receptors, inhibiting phospholipase A2, and reducing prostaglandin and leukotriene synthesis.
1-2 drops into the affected eye(s) every 4-6 hours; in severe disease, every 1-2 hours initially, then taper. Ointment: apply a 1/2-inch ribbon into the conjunctival sac 3-4 times daily.
1 drop into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be increased to 1 drop every 2 hours. Do not prescribe more than 20 mL per 30 days.
None Documented
None Documented
Tobramycin: 2-3 hours in adults with normal renal function; prolonged to 24-60 hours in anuria. Dexamethasone: 36-54 hours.
Tobramycin: 2-3 hours (prolonged in renal impairment; up to 50-70 hours in anuria); Dexamethasone: 3-4 hours
Tobramycin: ~90% renal (glomerular filtration), <1% biliary. Dexamethasone: hepatic metabolism, metabolites renally excreted.
Renal: ~60% as unchanged drug and inactive metabolites; Biliary: ~20%; Fecal: ~20%
Category C
Category C
Ophthalmic antibiotic/steroid combination
Ophthalmic antibiotic/steroid combination